Bernstein initiated coverage of Novartis (NVS) with a Market Perform rating and CHF 125 price target The firm sees five years of annual sales declines between 2031 and 2036 for Novartis. It thinks the stock can be viewed as “richly valued.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis Raises $11 Billion in Multi-Tranche U.S. Bond Offering
- Trump Trade: President issues short-term waiver of Jones Act
- Trump claims TrumpRx website offers lowest prices, review says not so, NYT says
- Novartis price target raised to CHF 95 from CHF 89 at HSBC
- District court rules federal limits to vaccines not based on science, NYT says